Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 3/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 5/20 | 0.43 |
| ▸ | RAB9A | P51151 | 5/20 | 0.43 |
| ▸ | CTNNB1 | P35222 | 2/20 | 0.43 |
| ▸ | WNT3A | P56704 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL549161 | 0.82 | SMN1; SMN2 (0.53) | TSHRMAPTSMN1; SMN2LMNAL3MBTL1 | |
| SCHEMBL8282238 | 0.78 | RAB9A (0.48) | TSHRMAPTSMN1; SMN2LMNAL3MBTL1 | |
| SCHEMBL7083041 | 0.76 | NNMT (0.50) | TSHRMAPTL3MBTL1KDM4EALDH1A1 | |
| SCHEMBL549253 | 0.75 | MAPT (0.52) | TSHRMAPTSMN1; SMN2LMNAKDM4E | |
| SCHEMBL34471843 | 0.74 | NNMT (0.48) | MAPTSMN1; SMN2L3MBTL1TDP1POLB | |
| SCHEMBL8525889 | 0.73 | ALDH1A1 (0.47) | TSHRMAPTSMN1; SMN2LMNAKDM4E | |
| SCHEMBL4638397 | 0.72 | NNMT (0.47) | TSHRSMN1; SMN2LMNAL3MBTL1TDP1 | |
| SCHEMBL30514062 | 0.72 | ALDH1A1 (0.62) | TSHRMAPTSMN1; SMN2LMNAL3MBTL1 | |
| SCHEMBL2182734 | 0.71 | DGAT1 (0.44) | TSHRL3MBTL1ALDH1A1TDP1POLB | |
| SCHEMBL624490 | 0.71 | TSHR (1.00) | TSHRMAPTSMN1; SMN2KDM4ENPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120129818-A1 | Compositions and Methods for Treatment of Cardiovascular Disease | CARMEL BIOSCIENCES, INC. | 2012-05-24 | — | — | US | disclosed |
| WO-2010124201-A2 | COMPOSITIONS AND METHODS FOR TREATMENT OF CARDIOVASCULAR DISEASE | INVASC THERAPEUTICS, INC. (US) | 2010-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120129818-A1 | Compositions and Methods for Treatment of Cardiovascular Disease | APOB, LDLR, APOL1 | TSHR 3638/4885MAPT 1463/4885SMN1; SMN2 2146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.